Adds details on the deal, background
Oct 5 (Reuters) – U.S. drugmaker Bristol Myers Squibb Co BMY.N said on Monday it would buy MyoKardia Inc MYOK.O for about $13 billion to expand its heart drugs business and reduce its dependence on cancer treatments.
Bristol Myers will pay $225 per share in cash, a 61.2% premium to MyoKardia’s Friday closing price.
The deal follows Bristol Myers’ $74 billion acquisition of Celgene Corp last year that combined two of the world’s largest cancer drug businesses in the biggest pharmaceutical deal ever.
With the deal for Myokardia, Bristol Myers will get access to mavacamten, a drug candidate for a chronic heart disease that affects up to 200,000 people across the United States and Europe.
Myokardia is expected to submit a marketing application for mavacamten to the U.S. health regulator in the in the first quarter of 2021.
Bristol Myers Squibb said it expects to explore mavacamten for additional indications and develop MyoKardia’s pipeline of other drugs.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Saumyadeb Chakrabarty)
(([email protected]; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.